Contingency management cut one-year mortality 41% in stimulant use disorder — the strongest evidence yet

A retrospective cohort study published in the American Journal of Psychiatry (PMC12872285) examined every veteran in the Veterans Health Administration who received contingency management (CM) for stimulant use disorder between July 2018 and December 2020, and matched them against comparable non-recipients. The headline finding: veterans who received CM were <span class="stat">41%</span> less likely to die in the year following treatment initiation. In sensitivity analysis, the adjusted hazard ratio held at <span class="stat">0.61</span> (95% CI: 0.38–0.98, p=0.043).

Why this is a big deal

There are <span class="stat">zero</span> FDA-approved medications for stimulant use disorder. That is not a typo. While opioid use disorder has methadone, buprenorphine, and naltrexone, and alcohol use disorder has acamprosate, naltrexone, and disulfiram, methamphetamine and cocaine use disorder are still treated primarily with behavioral interventions. CM — which provides tangible, low-value rewards (often gift cards) for biochemically verified abstinence — has the strongest evidence base among them. What it has lacked, until recently, is a clean mortality endpoint.

This study provides one. It pairs with the Wiley/Addiction cost-effectiveness paper we spotlighted on May 2 (<span class="stat">$9,830/QALY</span> at 12 weeks; <span class="stat">$12,312/QALY</span> at 24 weeks) to make CM one of the most cost-effective and life-saving interventions in addiction medicine — and one of the most chronically underused, because of historical anti-kickback concerns and an outdated clinical instinct to treat reward-based interventions as somehow less serious than medication.

What changed structurally

CMS and the VA have both quietly walked back the anti-kickback friction in the last two years. The VA’s StUD CM Program now operates at scale across multiple medical centers; CMS issued a 2025 guidance update clarifying that motivational incentives within published value caps do not implicate the Anti-Kickback Statute when integrated into formal SUD treatment. That regulatory door opening is a precondition for the kind of cohort the AJP paper analyzed even existing.

For Arizona providers and AHCCCS MCOs, CM remains underused — which means the V2 algorithm’s treatment-pathway logic should be giving stimulant users above-average weight to programs that explicitly offer it.

→ Read our spotlight: how contingency management actually works